## Systemic Antibiotic Management in Resistant CSOM **Key Point:** When CSOM fails topical therapy or is caused by fluoroquinolone-resistant Pseudomonas aeruginosa, systemic antipseudomonal therapy is required. Ceftazidime is a third-generation cephalosporin with excellent antipseudomonal activity and good penetration into infected middle ear tissue. **High-Yield:** Ceftazidime is the preferred systemic agent for resistant Pseudomonas in CSOM because it achieves high concentrations in bone and middle ear mucosa, and it covers both gram-negative (including resistant Pseudomonas) and gram-positive organisms commonly found in CSOM. **Clinical Pearl:** Fluoroquinolone resistance in Pseudomonas aeruginosa is increasingly common in chronic suppurative infections. In such cases, antipseudomonal beta-lactams (ceftazidime, piperacillin–tazobactam, or carbapenems) become the drugs of choice. ### Antipseudomonal Antibiotic Comparison | Agent | Pseudomonas Coverage | Route | Penetration to Middle Ear | Use in CSOM | |-------|----------------------|-------|--------------------------|-------------| | **Ceftazidime** | Excellent | IV/IM | Excellent | First-line for resistant cases | | **Piperacillin–tazobactam** | Excellent | IV | Excellent | Alternative | | **Meropenem** | Excellent | IV | Excellent | Reserved for severe/complicated | | **Amoxicillin–clavulanate** | Poor | Oral | Moderate | Ineffective against resistant Pseudomonas | | **Azithromycin** | Poor | Oral | Poor | Not for Pseudomonas | | **TMP–SMX** | Moderate | Oral | Moderate | Not preferred; resistance common | **Mnemonic:** **CAP-3** — Ceftazidime, Antipseudomonal beta-lactams, Piperacillin for Pseudomonas in 3rd-generation cephalosporins and beyond. **Warning:** Do not use amoxicillin–clavulanate or trimethoprim–sulfamethoxazole for resistant Pseudomonas; they lack sufficient antipseudomonal activity and will lead to treatment failure.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.